Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2-positive, Unresectable, Locally Advanced or Metastatic Breast Cancer”

52 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 52 results

Early research (Phase 1)Looking for participantsNCT07524322
What this trial is testing

Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors

Who this might be right for
Breast CancerOvarian CancerEndometrial Cancer+6 more
Regor Pharmaceuticals Inc. 63
Early research (Phase 1)Ended earlyNCT04042051
What this trial is testing

Copanlisib in Combination With T-DM1 in Pretreated Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer

Who this might be right for
HER2-positive Breast CancerMetastatic Breast CancerLocally Advanced Breast Cancer+1 more
Cancer Trials Ireland 2
Testing effectiveness (Phase 2)Active Not RecruitingNCT06172127
What this trial is testing

PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
MedSIR 165
Not applicableNot Yet RecruitingNCT07191405
What this trial is testing

Clinical Study of Chemotherapy and Immunotherapy Combined With Lactobacillus Johnsonii in Patients With Multiple Irresectable Solid Tumors

Who this might be right for
ImmunotherapyChemotherapy
Second Affiliated Hospital, School of Medicine, Zhejiang University 156
Not applicableWithdrawnNCT02616224
What this trial is testing

Observe Treatment Patterns and Outcomes in Patients With HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer, HER2 Positive Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer
Hoffmann-La Roche
Testing effectiveness (Phase 2)Active Not RecruitingNCT02849496
What this trial is testing

Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer

Who this might be right for
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Locally Advanced Unresectable Breast Carcinoma+1 more
National Cancer Institute (NCI) 81
Large-scale testing (Phase 3)Active Not RecruitingNCT07386938
What this trial is testing

The Efficacy, Safety and Pharmacokinetics of RPH-051 and Perjeta® in Combination With Trastuzumab and Docetaxel as the 1st Line Therapy in Patients With HER2-positive Breast Cancer

Who this might be right for
Locally Advanced Breast CancerMetastatic Breast Cancer
R-Pharm 246
Large-scale testing (Phase 3)Active Not RecruitingNCT05840211
What this trial is testing

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy

Who this might be right for
Locally Advanced or Unresectable Metastatic Breast CancerStage IV Breast Cancer
Gilead Sciences 654
Not applicableUnknownNCT04202328
What this trial is testing

T-DM1 in HER2-positive Metastatic/Relapsed Breast Cancer

Who this might be right for
Breast Cancer
Samsung Medical Center 1,000
Not applicableStudy completedNCT02393924
What this trial is testing

Human Epidermal Growth Factor Receptor 2 (HER2) Positive Unresectable Locally Advanced or Metastatic Breast Cancer Disease Registry Study

Who this might be right for
Breast Cancer
Hoffmann-La Roche 311
Large-scale testing (Phase 3)UnknownNCT05755048
What this trial is testing

FS-1502 Versus T-DM1 for HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. 314
Early research (Phase 1)Ended earlyNCT04060862
What this trial is testing

Ipatasertib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Hormone Receptor Positive and HER2 Negative Locally Advanced Unresectable or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 20
Testing effectiveness (Phase 2)Active Not RecruitingNCT05230810
What this trial is testing

Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.

Who this might be right for
HER2-positive Metastatic Breast Cancer
Criterium, Inc. 40
Large-scale testing (Phase 3)UnknownNCT04924699
What this trial is testing

MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Advanced Breast CancerMetastatic Breast Cancer
Shanghai Miracogen Inc. 350
Large-scale testing (Phase 3)Study completedNCT03262935
What this trial is testing

SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Byondis B.V. 437
Not applicableEnded earlyNCT02611310
What this trial is testing

Observe Treatment Patterns and Outcomes in Participants in Saudi Arabia With Human Epidermal Growth Factor Receptor 2 (HER2-Positive) Unresectable Locally Advanced or Metastatic Breast Cancer (LA/mBC)

Who this might be right for
Metastatic Breast Cancer
Hoffmann-La Roche 15
Testing effectiveness (Phase 2)Study completedNCT04539938
What this trial is testing

Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer

Who this might be right for
HER2 Positive Breast Cancer
Seagen, a wholly owned subsidiary of Pfizer 70
Testing effectiveness (Phase 2)WithdrawnNCT06105008
What this trial is testing

Study of Disitamab Vedotin With Toripalimab Verus Disitamab Vedotin in Hormone Receptor Positive, HER2-low Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Neoplasms
RemeGen Co., Ltd.
Testing effectiveness (Phase 2)Ended earlyNCT05091528
What this trial is testing

A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers

Who this might be right for
HER2-positive Breast CancerHER2-positive Gastric CancerHER2-positive Colorectal Cancer+1 more
Silverback Therapeutics 2
Large-scale testing (Phase 3)Study completedNCT04732598
What this trial is testing

A Phase III Study of Bevacizumab and Paclitaxel in Combination With Atezolizumab as a Treatment for Locally Advanced Unresectable or Metastatic Hormone Receptor-positive HER2 Negative Breast Cancer

Who this might be right for
Breast Cancer
Japanese Foundation for Cancer Research 281
Load More Results